| Document |
Document Title |
|
WO/2020/023768A1 |
This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering (a) one or more AKT inhibitors and/or one or more...
|
|
WO/2020/016210A1 |
The present invention relates to combinations comprising Calendula officinalis flower oil, Curcuma longa root extract, and Eugenia caryophyllus bud extract, and to their use in the treatment and/or prevention of vulvodynia. The invention...
|
|
WO/2020/013086A1 |
The present invention relates to a sperm fertility promoter comprising pyrroloquinoline quinone or a salt thereof.
|
|
WO/2020/012315A1 |
A terpene-enriched composition for treating conditions and/or symptoms associated therewith in a male subject is described, which composition comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount...
|
|
WO/2020/010919A1 |
A traditional Chinese medicine composition, a traditional Chinese medicine compound preparation and a preparation method therefor and the use thereof. The traditional Chinese medicine composition and traditional Chinese medicine compound...
|
|
WO/2020/006617A1 |
The present invention relates to smooth muscle tone modulating synthetic peptides. It also refers to pharmaceutical compositions containing such peptides and to the uses thereof in the treatment of disturbances in which the modulation of...
|
|
WO/2020/006606A1 |
The present disclosure relates to a pharmaceutical composition in a pharmaceutically acceptable vehicle. The pharmaceutical composition includes a physiologically effective, non-priapismic, dose of a penile-erection-inducing agent or a p...
|
|
WO/2020/008821A1 |
Provided is a composition to be used in a medicine, food, supplement, or beverage that is capable of treating, preventing, or improving male infertility. This composition for the treatment, prevention, or improvement of male infertility ...
|
|
WO/2020/007780A1 |
The invention relates to the field of human reproduction, more in particular to situations in which human reproduction is failing. The present invention provides reliable and highly accurate methods for predicting the chance that an assi...
|
|
WO/2020/004568A1 |
The present invention provides a novel means for promoting equol production in human intestines or a novel means for amelioration of premenstrual syndrome, which is related to such equol production, and for improving skin condition chang...
|
|
WO/2020/006191A1 |
A natural vaginal care composition is provided. The natural composition includes a biobased vaginal care agent; a biobased thickener; and at least 60% water. The natural composition may optionally include a biobased preservative, a bioba...
|
|
WO/2020/001460A1 |
Provided are a pharmaceutically acceptable salt, a crystal form of an azabicyclo substituted triazole derivative and a preparation method therefor. In particular, provided are a pharmaceutically acceptable salt, a crystal form of a compo...
|
|
WO/2020/006392A1 |
Compositions and methods for treating Trichomoniasis using topically administered antibiotics such as aminoglycosides, including streptomycin, spectinomycin, kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin...
|
|
WO/2019/242642A1 |
Provided are a pharmaceutically acceptable salt and crystal form of an OTR inhibitor and a preparation method thereof. In particular, provided are a pharmaceutically acceptable salt and crystal form of an OTR inhibitor 5-(3-(3-(6-fluoron...
|
|
WO/2019/242646A1 |
Provided are a polycrystal form of an oxytocin receptor (OTR) inhibitor compound 5-(3-(3-(6-fluoronaphthalen-1-yl)azetidin-1-yl)5-(methoxymet
hyl)-4H-1,2,4-triazol-4-yl)-2-methoxypyridine and a preparation method therefor. Relative to an...
|
|
WO/2019/238893A1 |
The present invention concerns the use of an inhibitor of interleukin- (IL-1), in particular of IL-1αand/or IL-1β, for the prevention or treatment of chronic histiocytic intervillositis (CHI) or a symptom associated thereof, eventually...
|
|
WO/2019/239268A1 |
A composition is described, comprising: lepidium meyenii walp; a pharmaceutically acceptable salt of manganese; vitamin E; a pharmaceutically acceptable salt of selenium and a pharmaceutically acceptable salt of zinc: alpha-lipoic acid, ...
|
|
WO/2019/235455A1 |
The present invention addresses the problem of providing: an enhancer of the fertilization function of a mammal sperm, which contains a low-molecular-weight compound that can be produced in a relatively simple manner and at relatively lo...
|
|
WO/2019/235451A1 |
Provided is a composition for treating menstrual symptoms, which contains α-lactalbumin. In addition, the present invention provides: a non-medical method for treating menstrual symptoms comprising a step of having a subject ingest a co...
|
|
WO/2019/227122A1 |
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production...
|
|
WO/2019/226755A1 |
The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are a...
|
|
WO/2019/223218A1 |
A traditional Chinese medicine transdermal patch for promoting blood circulation and clearing meridians to treat hyperplasia of the breast, comprising an adhesive layer, an energy layer, a magnetized layer, a medicinal film layer, and a ...
|
|
WO/2019/221531A1 |
The present invention relates to a composition for improving the vaginal health of women comprising poly-gamma-glutamic acid or a salt thereof. More specifically, the present invention provides a composition for improving the vaginal hea...
|
|
WO/2019/218543A1 |
The present invention relates to a combination for replacing Rhizoma Paridis Yunnanensis to prepare a drug for treating cervical cancer, a combination for replacing Rhizoma Paridis Yunnanensis to prepare a drug for treating ovarian cance...
|
|
WO/2019/222368A1 |
The present invention relates to amino acid salts of nicotinic acid mononucleotides and nicotinamide mononucleotides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in...
|
|
WO/2019/222360A1 |
The present invention relates to inorganic salts of nicotinamide mononucleotides and compositions of Formula (I), useful in the treatment of disorders and diseases associated with deficiencies in NAD+: Wherein A, M1, k, R1 and R2 are as ...
|
|
WO/2019/221813A1 |
The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+:wherein A is O"; M1 and M2 are indep...
|
|
WO/2019/221269A1 |
Provided are: a complex having an anti-human MUC1 antibody Fab fragment, a peptide linker and/or a ligand; a diagnostic composition and/or a medicinal composition comprising said complex; and a method for diagnosing and/or treating cance...
|
|
WO/2019/213690A1 |
An agent capable of promoting proliferation and differentiation of granulosa cells is disclosed which comprises a growth and differentiation factor-9 (GDF9) protein comprising a modified GDF9 polypeptide monomer which includes at least o...
|
|
WO/2019/213464A1 |
A method of treating vaginal atrophy is provided. The method comprises administering a vaginal care composition to vaginal tissue of a user experiencing a symptom of vaginal atrophy. The vaginal care composition may include an effective ...
|
|
WO/2019/213473A1 |
A method of treating vaginal dryness by administering a vaginal care composition, which includes an effective amount of a vaginal care agent, to vaginal tissue of a user experiencing vaginal dryness. The vaginal care agent may be selecte...
|
|
WO/2019/211153A1 |
Compositions including FSH and hCG for use in the treatment of infertility.
|
|
WO/2019/210134A1 |
A variety of different intravaginal drug delivery devices are described for the delivery of estrogens and progestins. The release rate of estrogens and progestins can be controlled by varying the matrix material or by the application of ...
|
|
WO/2019/208725A1 |
A pharmaceutical composition comprising abiraterone acetate ester particles having an average particle diameter of 50 to 200 nm and hydroxypropyl cellulose in an amount of 10 to 150% by mass relative to the content of abiraterone acetate...
|
|
WO/2019/208797A1 |
Provided is a novel compound that has an excellent β-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent β-lactamase inhibitory effect or a pharmaceutical...
|
|
WO/2019/208820A1 |
The present invention relates to: a complex that includes (1) nanoparticles, (2) an enzyme inhibitor–containing group represented by formula (A), (3) a ligand-containing group represented by general formula (L1) and supported by the su...
|
|
WO/2019/201713A1 |
The present invention relates to a therapeutically active compound for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring. ...
|
|
WO/2019/202508A1 |
The present invention concerns the formulation of a dietary supplement for the improvement of female fertility in the human species based on the use of a definite stoichiometry of resveratrol with different pharmacokinetic profiles. The ...
|
|
WO/2019/193052A1 |
The present invention relates to an isolated CD31+ cell derived from adipose-derived regenerative cells (ADRC's), for use as a medicament. The invention also relates to compositions comprising such cells. In addition, the invention relat...
|
|
WO/2019/186450A1 |
The present invention relates to anti-progestational agents of compounds of general formula (I) and process for the preparation thereof. The present invention further relates to pharmaceutical composition thereof and method of treatment ...
|
|
WO/2019/183872A1 |
A traditional Chinese medicine composition for treating diseases caused by human papillomavirus, comprising 15-60 parts of rhizoma smilacis glabrae, 7.5-30 parts of kuh-seng, 10-40 parts of oldenlandia diffusa, 10-40 parts of dandelion, ...
|
|
WO/2019/189772A1 |
In the present description, a cancer-treating agent is provided, which contains at least one component selected from a TM4SF1AS1 expression inhibitor, a PURA expression inhibitor and a YB1 expression inhibitor.
|
|
WO/2019/182975A1 |
A formulation consisting of at least one Alpha Hydroxy Acid in a carrier composition useful for the treatment of inflammation arising from the presence of microbiofilms on tissues of the human body where pathogens nucleate and reproduce ...
|
|
WO/2019/182981A1 |
The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering ...
|
|
WO/2019/180133A1 |
The invention relates to intravaginal devices, in particular rings,comprising progesterone in a particular polymorphic purity, methods for making such devices and therapeutic uses of said devices. In particular, the intravaginal devices ...
|
|
WO/2019/180217A1 |
The present invention relates to the use of a composition in a non-hormonal contraception method for a male subject, comprising administering an alpha-1-adrenoreceptor antagonist; wherein the contraception method includes a once daily ad...
|
|
WO/2019/177132A1 |
Provided is an orally disintegrating tablet that contains (6R,l2aR)-6-(1,3-benzodioxole-5-yl)-2-methyl-2,3,6,7,12,l2a-
hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione and allows for improved photostability. The orally disintegr...
|
|
WO/2019/175449A1 |
The present invention relates to a method of preparing magnetic oocytes and/or embryos by means of nanoparticles for assisted reproduction techniques and for use in assisted reproduction techniques of non-human oocytes and/or embryos pre...
|
|
WO/2019/178304A1 |
The present disclosure provides solid state forms of Relugolix, crystalline forms of Relugolix, pharmaceutical compositions thereof, and pharmaceutical formulations thereof. Methods for producing these forms of Relugolix, pharmaceutical ...
|
|
WO/2019/175864A1 |
The present invention relates to delivery devices adapted to mechanically dilate a pelvic anatomical canal, the delivery devices comprise a composition formulated as a gel comprising a beneficial or therapeutic agent, said delivery devic...
|
